LifeStance Health Group, Inc. (LFST)
割高ファンダメンタル
58
株価
$12.03
時価総額
$4.57B
パート1 · 企業の価値
概要
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users
Its behavioral health division has been adding outpatient mental-health locations across the US, competing market by market with LifeStance for the same commercially insured patients.
A privately held multi-state outpatient psychiatry and therapy group with 80+ clinics plus telehealth, competing for the same insured US patients and the same clinicians as LifeStance's hybrid clinic model.
A private national psychiatry practice in network with more than 60 US insurers, competing directly for the insurance-covered psychiatry and medication-management visits that are LifeStance's core revenue.
Offers insurance-covered virtual therapy and psychiatry to US consumers and employers, competing for the same outpatient mental-health visits that LifeStance delivers by telehealth.
A private platform that puts independent US therapists and psychiatrists in network with commercial payors, competing with LifeStance both for patients looking for an in-network clinician and for the clinicians themselves.
Through BetterHelp it is the largest virtual therapy brand in the US and is moving from cash-pay to insurance coverage, meeting LifeStance on the same outpatient therapy demand.
貸借対照表と流動性
売上高
$1.58B
直近12か月（2026/6/30まで）
純利益
$51M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$110M
自己資本合計
$1.52B
負債合計
$683M
流動比率
1.38
利払い倍率
7.75
負債/EBITDA
7.21
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$8.76
現在株価
$12.03
安全マージン
-37.4%
適正価値レンジ
$5.69 - $11.82
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
92.54
ROE
0.6%
P/B レシオ
3.11
P/FCF
26.43
粗利益率
-
ROIC
3.3%
収益性レーダー
価値創造（経済的モート）
ROIC
3.3%
WACC
11.1%
ROIC − WACC
-7.8 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（13）
- EPS shows upward trend
- P/FCF 26.43
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Return on Tangible Assets
- Revenue Growth 5Y 30.4%
- Analyst Consensus 78% Buy
- Earnings Surprise avg 621.9%
- Earnings Quality (OCF/NI) 4.31
- Net Margin Trend 3.2% vs -1.2%
- Piotroski F-Score 7/9
不合格（11）
- Price CAGR 4.88%
- ROIC 3.2%
- P/B Ratio 3.11
- Operating Margin 4.9%
- CapEx intensity
- Debt/EBITDA
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.4%
- Share Dilution 26.2%
データなし（3）
- Gross Margin NaN%
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
財務健全性が高い
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
新株を発行しており、所有権を希薄化している
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Kenneth Alan Burdick J.D. | Executive Chairman | 66 |
| Mr. David Patrick Bourdon | CEO & Director | 56 |
| Mr. Ryan Bruce McGroarty | CFO & Treasurer | 52 |
| Mr. Vukasin Paunovich | Chief Technology Officer | 53 |
| Mr. Ryan Pardo J.D. | Chief Legal Officer & Secretary | 48 |
| Ms. Ann Varanakis | Chief People Officer | 47 |
| Ms. Lisa Keise Miller | Chief Operating Officer & Principal Operating Officer | 51 |
| Ms. Monica Prokocki | Vice President of Investor Relations | - |
| Brooke Matthews | Director of Public Relations | - |
| Mr. Richard Hall | Chief Shared Services Officer | - |
監査リスク
10
取締役会リスク
10
報酬リスク
7
株主権利リスク
8
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for LFST, sourced from Markets Gazette.
- 2/25/2026NEUTRALLifeStance (LFST) Q4 2025 Earnings Call Transcript
The transcript for LifeStance Health Group, Inc.'s (LFST) Q4 2025 earnings call is now available. Investors and analysts have been keenly awaiting this document to gain in-depth insights into the company's financial performance for the period. While the specific content has not been disclosed in this announcement, the release of the transcript is a crucial event for market transparency. Market participants will now focus on analyzing management's statements, future projections, and responses to analyst questions to assess LifeStance's operational health and growth prospects. The market's reaction will hinge on the key metrics presented and the guidance provided.
via Markets Gazette